Case report: the remarkable response of pembrolizumab combined with rc48 in the third-line treatment of metastatic urothelial carcinoma

HIGHLIGHTS

• who: Zhenying Xu and colleagues from the Fudan University, China have published the research: Case report: The remarkable response of pembrolizumab combined with RC48 in the third-line treatment of metastatic urothelial carcinoma, in the Journal: (JOURNAL) of 25/04/2012

SUMMARY

Disitamab Vedotin (RC48), an ADC designed for HER2, has demonstrated promising therapeutic efficacy in advanced UC and has received Breakthrough Therapy Designation from the FDA as second-line treatment for patients with advanced UC with high HER2 expression, including immunohistochemistry (IHC) 2+ or 3+. In January 2022, RC48 was endorsed by . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.